J9319 Injection romidepsin lyophil 0.1mg
Also known as: romidepsin, Istodax
Injection of romidepsin lyophilized formulation, 0.1 milligram. A histone deacetylase inhibitor for cutaneous T-cell lymphoma.
In Plain Language
lymphoma injection; T-cell cancer treatment
Clinical Context
Lyophilized formulation of romidepsin for cutaneous T-cell lymphoma therapy. Freeze-dried formulation for enhanced stability.
RVU Information
CPT J9319 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9319?
CPT J9319 (Injection romidepsin lyophil 0.1mg) is a J Codes (Drugs) code. Injection of romidepsin lyophilized formulation, 0.1 milligram. A histone deacetylase inhibitor for cutaneous T-cell lymphoma.
How is J9319 administered?
CPT J9319 is administered by a healthcare provider, typically via injection or infusion. Lyophilized formulation of romidepsin for cutaneous T-cell lymphoma therapy. Freeze-dried formulation for enhanced stability. It is used by Oncology, Dermatology, Hematology.
When is CPT J9319 used?
Lyophilized formulation of romidepsin for cutaneous T-cell lymphoma therapy. Freeze-dried formulation for enhanced stability.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.